LONDON: Oxford University, in collaboration with AstraZeneca, announced interim trial data from its Phase III trials that show its candidate vaccine is 70.4% effective when combining data from two dosing regimens.
“There were no hospitalised or severe cases in anyone who received it,” pharmaceutical firm AstraZeneca said in a Monday news release.
As AstraZeneca became the latest drugmaker to release encouraging Covid-19 vaccine trial results on Monday, UK Health Secretary Matt Hancock also said that his government hopes to start vaccinating people in December, pending approval.
UK Prime Minister Boris Johnson tweeted on Monday that the results from AstraZeneca’s experimental vaccine trials were “incredibly exciting.”
Incredibly exciting news the Oxford vaccine has proved so effective in trials. There are still further safety checks ahead, but these are fantastic results. Well done to our brilliant scientists at @UniofOxford & @AstraZeneca, and all who volunteered in the trials. https://t.co/84o8TKhQga— Boris Johnson (@BorisJohnson) November 23, 2020
The UK government has ordered 100 million doses of the AstraZeneca vaccine and 40 million doses of the Pfizer/BioNTech vaccine.
Serum Institute of India partnered with AstraZeneca to support Oxford University’s efforts for a vaccine.